Scholar Rock

Market position

A third-party profile characterizes Scholar Rock as a global biopharmaceutical company focused on children and adults with spinal muscular atrophy and other rare, severe neuromuscular diseases, describing it as a leader in muscle biology and growth factor modulation with clinical proof of concept in SMA via myostatin pathway targeting and late-stage momentum from Phase 3 SAPPHIRE data. The same source lists comparable companies including Arrowhead Pharmaceuticals, Editas Medicine, bluebird bio, Biogen, Vertex Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, Amgen, Codiak BioSciences and Generation Bio.

Scholar Rock states that its approach selectively targets latent, pre-activation forms of growth factors, which it contrasts with traditional approaches that address growth factor activity after activation (analogized on its site to shutting off a water supply rather than mopping up a spill). It attributes potential advantages to selectivity within the TGFβ superfamily, which it says may overcome limitations of earlier therapeutic approaches that lacked selectivity. A third-party profile similarly characterizes the platform as proprietary monoclonal antibodies with high selectivity within the TGFβ superfamily, and notes clinical proof of concept in SMA via myostatin pathway targeting.

Technology

The platform is based on a discovery in the biology of the TGFβ superfamily that allows selective targeting of the latent (pre-activation) forms of protein growth factors, enabling regulation of growth factor activation in specific cell types and tissues within the disease microenvironment; BioSpace's 2014 coverage described these as "niche modulators" designed for localized effect and reduced systemic exposure. Programs are proprietary monoclonal antibodies directed at latent myostatin (apitegromab, SRK-439), latent TGFβ1 in both context-independent (SRK-181) and context-dependent LTBP1/LTBP3 forms (SRK-373), and RGMc/hemojuvelin (SRK-256). A third-party profile lists corporate IT tooling including Azure Active Directory, Microsoft Active Directory, Microsoft Office, PowerShell, Microsoft SharePoint Online, Genesis Framework, OpenResty and Twitter widgets, and Lever as its applicant tracking system.

Go-to-market

As a clinical-stage developer, Scholar Rock advances candidates through clinical trials and regulatory submissions, engaging patients and families through disease-focused resources, patient stories, clinical trial information and expanded access programs on its website, and communicating with the SMA community through update letters. It maintains investor relations activity including presentations at healthcare investor conferences (for example, BofA Securities and Goldman Sachs healthcare conferences) and scientific conferences such as the MDA Conference, Cure SMA Research and Clinical Care Meeting and the international research congress on FSHD. The company also lists a partnering program for collaborations.

Patients with serious diseases in which growth factors play a central role, including children and adults with spinal muscular atrophy and other rare neuromuscular diseases such as facioscapulohumeral muscular dystrophy, patients with locally advanced or metastatic solid tumors, fibrotic diseases and iron-restricted anemia, together with their families, treating healthcare professionals and clinical investigators.

Geography

Headquarters are at 301 Binney Street, 3rd Floor, Cambridge, MA 02142 (previously 620 Memorial Drive, Cambridge, MA 02139 at the time of the 2018 S-1 filing). A third-party profile describes employees across four continents including North America, Europe and Asia, and lists roles such as VP Market Access EMEA and Vice President & EMEA Finance Head, indicating a European presence.

History

The company was founded on research from Harvard Medical School and Boston Children's Hospital by Timothy Springer and Leonard Zon, who developed an approach to targeting protein growth factors based on their molecular mechanisms of activation. In September 2014 the company, then described as a Cambridge, Massachusetts biotech startup led by CEO and President Nagesh Mahanthappa with Amir Nashat of Polaris Partners as chairman, announced a $20 million Series A round. In April 2018 Scholar Rock Holding Corporation filed a Form S-1 for an initial public offering, then headquartered at 620 Memorial Drive, Cambridge, MA, seeking to list on The Nasdaq Global Market under the ticker SRRK. The company subsequently traded publicly as NASDAQ: SRRK, advanced apitegromab through a Phase 3 SAPPHIRE trial with data presented at the 2025 MDA Conference, and, according to a third-party profile, raised a $300 million financing dated March 2026 intended for regulatory submissions and launch preparation. It is now located at 301 Binney Street, Cambridge, MA.

Risks & controversies

The 2018 Form S-1 notes that investing in the company's common stock involves risks and includes a risk factors section, and states the company qualifies as an emerging growth company subject to reduced public company reporting requirements. The pipeline includes only investigational products not approved by the FDA, and the anticipated U.S. launch of apitegromab is expressly contingent on regulatory approval following a BLA resubmission. The company posted an update regarding a third-party manufacturing site in October 2025. Scholar Rock also warns on its careers page about fraudulent job postings and offers made in its name by scammers.